# OnCo record nct06082167 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/nct06082167/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "nct06082167", "NCT06082167" ;
  schema:name "Study of Zanzalintinib (XL092) + Pembrolizumab vs Pembrolizumab in Subjects With PD-L1 Positive Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma"@en ;
  schema:alternateName "STELLAR-305"@en ;
  schema:description "A phase 2/3 trial testing Zanzalintinib in head and neck squamous cell carcinoma, active and no longer recruiting."@en ;
  schema:url <https://onco.cc/trials/nct06082167/> ;
  schema:dateModified "2026-09-11"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT06082167> ;
  onco:status "active" ;
  onco:tag "ctgov-ingest" ;
  onco:phase "2/3" ;
  schema:startDate "2024-06-07" ;
  onco:cancers <https://onco.cc/cancers/head-and-neck/>, <https://onco.cc/cancers/recurrent-metastatic-hnscc/> ;
  onco:drugs <https://onco.cc/drugs/zanzalintinib/> ;
  onco:companies <https://onco.cc/companies/exelixis/> .